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Abstract: Expression of the pro-angiogenic vascular endothelial growth factor (VEGF) 
stimulates angiogenesis and correlates with the progression of osteoarthritis. Mechanical 
joint loading seems to contribute to this cartilage pathology. Cyclic equibiaxial strains of 
1% to 16% for 12 h, respectively, induced expression of VEGF in human chondrocytes 
dose- and frequency-dependently. Stretch-mediated VEGF induction was more prominent 
in the human chondrocyte cell line C-28/I2 than in primary articular chondrocytes. Twelve 
hours of 8% stretch induced VEGF expression to 175% of unstrained controls for at least 
24 h post stretching, in promoter reporter and enzyme-linked immunosorbent assay (ELISA) 
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studies. High affinity soluble VEGF-receptor, sVEGFR-1/sFlt-1 was less stretch-inducible 
than its ligand, VEGF-A, in these cells. ELISA assays demonstrated, for the first time,  
a stretch-mediated suppression of sVEGFR-1 secretion 24 h after stretching. Overall, 
strained chondrocytes activate their VEGF expression, but in contrast, strain appears to 
suppress the secretion of the major VEGF decoy receptor (sVEGFR-1/sFlt-1). The latter 
may deplete a biologically relevant feedback regulation to inhibit destructive angiogenesis 
in articular cartilage. Our data suggest that mechanical stretch can induce morphological 
changes in human chondrocytes in vitro. More importantly, it induces disturbed VEGF 
signaling, providing a molecular mechanism for a stress-induced increase in angiogenesis 
in cartilage pathologies. 
Keywords: VEGF-A; VEGFR-1/FLT-1; sVEGFR-1/FLT-1; cyclic stretch; strain; human 
chondrocyte; C-28/I2 
 
1. Introduction 
In joint cartilages, chondrocytes are constantly deformed as a result of loading due to normal daily 
activities. Guilak et al. estimated compression of chondrocytes resulting from physiological loading to 
be approximately 20% [1]. Normal physiological loading is generally regarded as a prerequisite for  
the maintenance of proper articular joint functioning, while injurious loading can lead to cartilage 
degeneration [2]. Other forms of mechanical stimulation like mechanical stretch also elicit a response 
in primary bovine chondrocytes [3,4]. In normal, healthy human chondrocytes, cyclic stretch has been 
reported to be anabolic [5], while others report differentiation stage-dependent detrimental effects in 
osteoarthritic cells [6]. Excessive mechanical stress causes deterioration of the cartilage metabolism 
through induction of catabolic factors, including matrix metalloproteinases (MMPs) [4,7,8]. 
However, mechanical loading is an important environmental factor that regulates articular cartilage 
homeostasis and influences the biosynthesis of matrix components in vivo [9,10]. Mechanical overload 
induces cartilage destruction and secondary osteoarthritis [11] as evident from acute traumatic injury, 
abnormal weight bearing (i.e., obesity [12,13]) or altered joint geometries [14]. Being composed of  
a network of extracellular matrix components and scattered chondrocytes, healthy mature articular 
cartilage is essentially devoid of vasculature [15]. In osteoarthritis (OA), pro-angiogenic factors are 
produced by chondrocytes [16] and expression of vascular endothelial growth factor (VEGF) has been 
shown in the superficial zone of the tibial plateau in OA patients with degenerative changes, but not in 
healthy cartilage [17]. Pro-angiogenic stimuli alone might be insufficient to overcome the resistance of 
normal articular cartilage to neovascularization, which is at least partly due to its matrix composition [18]. 
Cartilage from patients with OA is also less able to remain avascular than healthy cartilage [19]. 
Abnormal mechanical stress might “awaken” adult chondrocytes to produce VEGF in order to increase 
their catabolic activity [7]. While VEGF plays an essential role in cartilage vascularization and 
endochondral bone development [20], Wong et al. [21] also showed that VEGF is significantly  
up-regulated by cyclic tension and hydrostatic pressure in chondrocytes. Not surprisingly, recent 
investigations also revealed higher expression levels of VEGF and its receptors in diseased cartilage, 
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such as in OA and rheumatoid arthritis (RA) [16,22–24]. Pufe et al. [25] further showed that VEGFA 
significantly increased matrix metalloproteinase (MMP) levels in cultured immortalized human 
chondrocytic C-28/I2 cells. Nevertheless, the precise mechanism by which VEGF might be involved in 
the pathogenesis of OA is not clearly understood. 
Being composed of a network of extracellular matrix components and scattered chondrocytes, healthy 
mature articular cartilage is essentially devoid of vasculature [15]. The mechanisms by which articular 
cartilage might be maintained as avascular have not been fully clarified. Chondrocyte hypertrophy is 
one of the key physiological processes involved in the longitudinal growth of long bones, but also in the 
development of OA [17,26]. Hypertrophy is accompanied by an up-regulation of collagen X, MMPs, 
and VEGF [26]. 
The VEGF family comprises at least seven members [27] of which VEGF-A, or simply VEGF [28], 
is the founding member encoded by the VEGF gene and thought to be of singular importance [29]. 
Hypoxia facilitates the binding of hypoxia-inducible factor 1 (HIF-1) to the hypoxia responsive 
element (HRE) in the 5' promoter region of the VEGF gene to induce its expression [30]. While VEGF 
binds to all VEGF receptors, its affinity to VEGFR-1 (or fms-like tyrosine kinase-1, Flt-1) is 10-fold 
higher than to VEGFR-2 (or kinase domain region (KDR)/fetal liver kinase-1, Flk-1) [31,32]. 
Therefore, VEGFR-1 is usually considered to act as a sink for VEGF isoforms [33,34]. Alternative 
splicing of VEGFR-1 also generates a soluble form, sVEGFR-1 (synonym: sFlt-1), which acts as an 
extracellularly circulating decoy receptor to negatively regulate VEGF activity [34]. Although expression 
of VEGF is pro-angiogenic and a potential challenge for physiologically avascular tissues, little is 
known about its induction or about the regulation of its receptors, like sVEGFR-1. 
With the present study, we aimed to investigate the intersection between VEGF signaling pathways 
and mechanosensation in chondrocytes. Specifically, we wondered if VEGF, its high affinity receptor 
VEGFR-1 and its endogenous inhibitor sVEGFR-1 are differentially regulated by different magnitudes 
of stretch. 
2. Results and Discussion 
2.1. Results 
First, we subjected C-28/I2 cells and primary chondrocytes to a 12 h cyclic stretching regime using 
cyclic square waveforms. We correlated the amount of relative stretching of the BioFlex® silicone 
bottom membrane and its frequency to VEGF expression in these cells: a range of 1% to 16% of 
stretch at 0.5 or 1 Hz, respectively, was evaluated and normalized to the non-stretched controls. 
Using square waveforms, low frequency (0.5 Hz) stimulation strain dose-dependently induced 
VEGF secretion to 160% in C-28/I2 cells (Figure 1A) immediately after the stretching regime at 
maximal elongation (i.e., 16%). Under these conditions, modest stretching of only 1% already induced 
VEGF secretion by 25% and 4% stretch by 50%, respectively. 
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Figure 1. Strain-dependent vascular endothelial growth factor (VEGF) expression in  
C-28/I2 cells. Chondrocytes were strained in a FX-4000T system for 12 h. Using square 
waveforms and 0.5 Hz at 0%, 1%, 4%, 8%, 12% and 16% of strain (A and B, respectively), 
VEGF expression was quantified immediately (t0) (A and C, respectively) or 24 h post 
stretching (B and D, respectively) using a VEGFA-specific enzyme-linked immunosorbent 
assay (ELISA). The experiment was repeated at 1 Hz using only 0%, 1%, 4%, and 8% of 
strain (C and D, respectively). All values are normalized to the unstrained, parallel controls 
(set to 1). *, **, and *** indicate significance levels of p ≤ 0.05, p ≤ 0.01, and  
p ≤ 0.001 respectively, n = 5. 
 
Stretch-induced VEGF secretion continued in resting cells: 24 h after the cyclic stretching,  
strain-dependent VEGF secretion reached 220% (i.e., 206 pg/mL) of the control level at 16% 
elongation and increased to more than 150% in the 1% stretch condition (Figure 1B). Doubling the 
stretch frequency to 1 Hz initially suppressed VEGF secretion at very low elongation rates (i.e., 1% 
stretch), while 4% of stretch resulted in a similar, about 50%, induction of VEGF secretion as 
compared to 0.5 Hz. Surprisingly, while 0.5 Hz showed an almost linear dose-response between strain 
levels and VEGF secretion, VEGF secretion at 1Hz dropped already at 8% of stretch immediately after 
stretching (Figure 1C). Low end stretch of 1% did also not further induce VEGF secretion upon  
non-stretched incubation under these conditions. In contrast, VEGF secretion reached 240% of the 
control level upon 24 h of non-stretched incubation at only 4% stretch, indicating a continuous 
secretion of this pro-angiogenic cytokine beyond the point of direct straining (Figure 1C vs. 1D).  
This is also 29% more than at the highest stretch level of 16% at 0.5 Hz and about 65% more than at 
the 4% stretch at 0.5 Hz. Doubling the stretch level to 8% did not further increase the VEGF 
concentration in the culture medium. Rather, a relative drop of about 25% was observed, roughly 
mirroring the VEGF secretion pattern directly after stretching. At 1 Hz, VEGF secretion was maximal 
at 4% of stretch independent of the timing. 
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In primary articular chondrocytes (Figure 2), the strain-dose response with square waveforms at  
0.5 Hz was less linear than in C-28/I2 cells. While the VEGF secretion ascended in C-28/I2 with 
increasing stretch levels between 1% and 16%, in primary chondrocytes a plateau was reached at 4% 
of stretch immediately after stretching (Figure 2A). Between 4% and 16% of stretch, VEGF secretion 
appeared relatively independent of the applied strain level also upon 24 h of non-stretched incubation 
(Figure 2B). VEGF secretion in primary cells at 4% reached 128% and was thus virtually identical to 
the level in C-28/I2, immediately after straining (Figure 2A vs. 1A). Increasing the frequency to 1 Hz 
did not enhance VEGF secretion in primary chondrocytes (Figure 2A vs. 2C). No significant elevation 
of VEGF levels was found after 24 h of non-stretched incubation (Figure 2D). 
Figure 2. Strain-dependent VEGF expression in primary chondrocytes. Cells were strained 
for 12 h with cyclic waveforms and a variety of relative strains. VEGF expression was 
analyzed directly after straining (t0) (A and C, respectively) or 24 h post stretching (B and D, 
respectively). The figures show data obtained with square waveforms at 0.5 Hz (A,B)  
and 1.0 Hz (C,D). Relative percentages of stretching are indicated (i.e., 4%, 8%, 12% or 
16%, respectively). Unstrained controls (ctrl) were used to normalize data (set to 1). *, **, 
and *** indicate significance levels of p ≤ 0.05, p ≤ 0.01, and p ≤ 0.001 respectively, n = 3. 
 
Next, we used dual-luciferase-assays to verify stretch-induced VEGF biosynthesis; stretching human 
chondrocytes induced the VEGF promoter activity in these cells to 175% of the control level (Figure 3A). 
In comparison, upon 8% stretching at 0.5 Hz, VEGF secretion increased to 150% (Figure 1A). 
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Figure 3. Stretch-mediated activation of VEGF promoter activity. Dual luciferase reporter 
assays were used to screen VEGF promoter activation upon stretching. C-28/I2 chondrocytes 
were transfected with a VEGF-promoter specific reporter construct (pVEGF-KpnI), 
expressing inducible Firefly luciferase, and a constitutive active Renilla luciferase for 
normalization purposes. Cells were stretched (8%, 0.5 Hz, 12 h square waveforms (A) and 
the ratio of Firefly-to-Renilla signals is shown. The unstrained control (ctrl) is set to 100% 
(i.e., 1); HRE activity (B) was measured using a Hypoxia Responsive Element (HRE) 
reporter construct (pGL3-HRE). Unstrained controls (ctrl), stretched cells (strain). ** indicates 
p ≤ 0.01, n.s. = not significant; n = 5. 
 
Binding of HIF-1α to the HRE in the 5' promoter region of the Vegf gene can induce its expression [30]. 
For that reason, we used a pGL3: HRE-luc vector as a negative control. Under normoxic conditions, 
when HIF-1α is unstable, stretch alone is not able to activate transcription of this reporter  
(Figure 1B). Our data confirm a stretch-specific, HIF-1α independent, induction of Vegf transcription 
in human chondrocytes. 
Finally, we confirmed the induction of VEGF expression on cellular level in human C-28/I2 
chondrocytes. Upon 12 h of 8% cyclic square waveforms stretching at 0.5 Hz, increased green 
fluorescent signals indicated the induction of VEGF biosynthesis (Figure 4C vs. 4B). Non-strained 
control cells revealed only very faint VEGF signals, indicating a very modest basal expression level 
(Figure 4B). Controls lacking the primary antibody were only positive for nuclear counterstaining 
(blue, Figure 4A). VEGF has a predominant high affinity receptor: VEGFR-1. Therefore, we next looked 
into the strain-dependency of its expression, too. In contrast to its prime ligand, VEGFR-1-specific 
immunosignals were already quite prominent in non-stretched cells (Figure 4E) and appeared to be 
cytoplasmic as well as nuclear. Surprisingly, 8% of stretching hardly decreased VEGFR-1-specific 
staining intensity in these cells (Figure 4F). 
VEGFR-1 is considered to be a sink for VEGF isoforms and alternative splicing can give rise to its 
soluble form, sVEGFR-1. We therefore postulated that the latter may act as a potential extracellular 
decoy receptor to inhibit VEGF-induced angiogenesis in cartilage, and aimed at quantifying the 
amount of strain-induced sVEGFR-1 secretion. Using square cyclic waveforms at 0.5 Hz, sVEGFR-1 
secretion increased only about 20% immediately after 8% of stretching. Neither 1% nor 4% stress 
significantly increased its secretion level (Figure 5A). Of note, after 24 h, the trend in strain-induced 
sVEGFR-1 secretion reversed and revealed suppression for ≥4% of initial stretching (Figure 5B). 
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Figure 4. Expression of VEGF and VEGFR-1 in human chondrocytes. Representative 
immunofluorescent staining of VEGF and VEGFR-1 in C-28/I2 chondrocytes. Cells were 
strained for 12 h with cyclic square waveforms at 0.5 Hz and 8% relative stretching. Green 
Alexa Fluor® 488-specific signals for VEGF (top row) and VEGFR-1 (bottom row) are 
shown, while nuclei appear in blue (bisbenzimid). Staining control without primary antibody 
(immuno ctrl: A,E); unstrained cells (B,F), strained (i.e., stretched) cells (C,G). Scale bars 
represent 100 μm. Signal intensity of the anti VEGF staining (D) and VEGFR-1/Flt-1 (H) 
was quantified by ImageJ. Signal intensity of unstrained cells was set to 1. * indicates  
p ≤ 0.05, n = 3. 
 
Figure 5. Stretch dependency of sVEGFR-1 expression in C-28/I2. Cells were stretched 
for 12 h with cyclic waveforms and a variety of relative strains. Expression of soluble 
decoy VEGF receptor: sVEGFR-1 was analyzed directly after straining (t0) (A) or 24 h 
post straining (B), using cyclic square waveform at 0.5 Hz. Relative percentages of 
stretching are indicated (i.e., 1%, 4% or 8%, respectively). Unstrained controls (ctrl) were used 
to normalize data (set to 1). * and *** indicate significance levels of p ≤ 0.05 and p ≤ 0.001 
respectively, n = 3. 
 
To exclude strain-induced changes in C-28/I2 viability, we determined the metabolic activity of  
cells stretched with 8% at 1Hz, which resulted in a reduced VEGF expression as compared to 4%  
stretch (Figure 1C,D). Using cyclic square waveforms only marginally, but significantly, reduced 
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metabolic activity in C-28/I2 cells (Figure 6). The same trend was seen immediately after stretching as 
well as 24 h later. 
Figure 6. Effect of strain on cell viability. C-28/I2 chondrocytes were stretched (8%) for 
12 h with cyclic square waveforms at 1 Hz. Cell viability was assessed using CellTiter 
Blue® directly after straining (t0) or 24 h later, and is expressed as relative fluorescent 
signal (560 nm/590 nm ratio). Unstrained controls (ctrl), stretched cells (strain). * and ** 
indicate significance levels of p ≤ 0.05 and p ≤ 0.01, respectively, n = 3. 
 
Using scanning electron microscopy (SEM), we confirmed the typical polygonal morphology  
of C-28/I2 cells. Strained cells (Figure 7B,D) showed a more prominently pronounced nucleus as 
compared to non-stretched cells (Figure 7A,C). In addition, they revealed a higher averaged 
nucleus/cytoplasm ratio as the cytoplasm of strained cells appeared more condensed and cells revealed 
characteristic knot-like condensations at the cellular periphery (Figure 7D). The latter could be caused 
by adhesive structures. Furthermore, the cellular protrusions (i.e., filopodia) appear more directed, 
possibly aligned in the direction of the strain. Stretched cells also reveal characteristic knot-like 
condensations at the cellular periphery (Figure 7D). 
Figure 7. Morphological changes in stretched chondrocytes. C-28/I2 cells were stretched 
(8%) for 12 h using cyclic square waveforms at 0.5 Hz and immediately fixed on the 
silicone membrane. Shown are representative scanning electron micrographs of unstrained 
cells (strain ctrl: A,C) and stretched cells (strain: B,D). Scale bars represent 25 μm. n = 3. 
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2.2. Discussion 
Mechanical forces are believed to substantially contribute to the onset and progression of 
osteoarthritis [11,35,36], affecting about 2% of the population [37]. Expression of pro-angiogenic 
vascular endothelial growth factor (VEGF) stimulates angiogenesis and also correlates with OA [38]. 
This suggests an active role of this cytokine in this pathogenesis and has been confirmed in a murine 
model [37]. In the present study, we showed that cyclic stretch dose- and frequency-dependently 
induced VEGF expression in primary human articular chondrocytes as well as in a chondrocytic cell 
line. We did not investigate mRNA expression of hypertrophic markers, but rather focused on the 
expression of VEGF signaling molecules at the protein level. 
A 7% cyclic tensile strain of 0.5 Hz for 24 h did affect MMP-13 expression in rat chondrocytes [39], 
which is in line with the observed VEGF induction in our experiments, as MMP-13 and VEGF are 
both reported to be Runx-2 dependent [40]. Stretching chondrocytes at 0.5 Hz showed an almost linear 
dose-response between strain levels and VEGF secretion. Intriguingly, at 1 Hz, 4% of stretching 
induced the largest VEGF secretion (Figure 1C,D). Alternative splicing of the primary VEGF  
pre-mRNA transcript produces at least five different isoforms of which VEGF-121 is totally released 
into the supernatant, whereas 70% of VEGF 165 may remain trapped into the extra-cellular matrix 
(ECM) [41]. To our knowledge, only two other studies have investigated the effect of strain frequency 
on skeletal cells before: one study by our group [42] reported frequency-dependent VEGF-121 and  
-165 syntheses in tendon fibroblasts at 1 Hz, but not at 0.5 Hz. The other study [43] used ROS17/2.8 
rat osteosarcoma cells. Using our type of straining device and an ELISA assays from the same 
company, Faure et al. further found that low frequencies (≤0.25 Hz) increased VEGF secretion into  
the supernatant (1.5- and 1.2-fold, respectively), while higher frequencies (≥2.5 Hz) had no effect or 
decreased VEGF release, which is thus negatively correlated with the stretching frequency.  
The authors hypothesized that relaxed and pulse mode-driven alternative start codon usage shifts 
VEGF isoform expression in a stress-fiber dependent manner. Intriguingly, both VEGF and 
mechanical stimuli regulate stress fiber formation in skeletal cells [44]. As cytoskeletal integrity is a 
prerequisite to mechanosensitivity [45], we speculate that not only frequency, but also the magnitude 
of stretching can influence VEGF release in a similar way. 
Our stretch-mediated VEGF release is rather moderate. Others also reported plenty of evidence 
across cell types suggesting that even moderate changes in VEGF levels can be biologically 
meaningful with respect to stimulating angiogenesis [43,46,47], and that 10% cyclic stretch at 1 Hz 
can increase sprouting angiogenesis [48]. Interestingly, cyclic uniaxial stretch apparently is a  
pro-angiogenic stimulant, like VEGF itself, and a synergistic effect between stretching and VEGF was 
found for especially the low, not high, cytokine concentrations. A not even 2-fold increase in  
VEGF secretion (173.4 vs. 275.73 pg/mL) by keratinocytes was found to stimulate local blood  
vessel formation [49]. Stretching elicited a similar fold-change of VEGF secretion, with concentrations 
around 200 pg/mL, by chondrocytes. We therefore believe this may be sufficient to stimulate 
angiogenesis in vivo, too. 
In the present study we showed that different types of chondrocytes release VEGF upon mechanical 
stimulation. In vivo mechanical information is delivered to chondrocytes through various types of 
stimuli (i.e., compression, tension, and fluid-flow or piezoelectric currents) all characterized by various 
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amplitudes and frequencies. One limitation of our study is that we cannot easily translate our results to 
forces in situ. We found that relatively low strains are sufficient to induce VEGF in chondrocytes in 
monolayer culture, while others have described detrimental effects not below 16% of stretch at 0.5 Hz 
in other cells [50]. 
VEGF expression is known to be up-regulated through activation of ERK signaling, which is 
inducible by mechanical stretch [51]. Within the VEGF 5'-flanking region, negative and positive 
stretch-response elements have been identified [52]. Analysis of the human VEGF gene promoter 
sequence also revealed several consensus transcriptional response elements like AP-1, AP-2 and 
GATA-6, which are known molecular targets of MAPK signaling [53]. Of note, 5% of cyclic strain at 
1 Hz for 24 h induced ERK and activated a mechano-sensitive HIF-1α element in the VEGF promoter 
inducing VEGF and, subsequently, MMPs [54]. The latter may be a sign of “injurious” strain levels.  
In closely related skeletal cells, HIF1α trans-activates Vegf and mechanical strain also was shown 
earlier to induce both Hif1α and Vegf expression in related cell types [43]. Even normoxic myocardial 
cells under mechanical stress induced HIF1α, and subsequently VEGF [55]. Surprisingly, we could not 
demonstrate HRE activation by stretch, which makes HIF1α involvement in our experiments unlikely. 
That 7.5% of stretch at 1 Hz in a FlexerCell system induced MMP13 expression in articular 
chondrocytes [56] is supportive of our notion that a hypertrophic pathway (i.e., collagen X expression) 
may be activated by cyclic tension in our chondrocytes [57]. As key factors of mechanotransduction, 
NO donors may also contribute to the VEGF induction [58]. Likewise, VEGF receptor signaling also 
involves calcium release and MAPK activation [59], both of which are known to be regulated by 
stretch [60–62]. It would be interesting to study their contribution to VEGF signaling in future studies. 
The strain-mediated VEGF release of primary chondrocytes and immortalized cells slightly 
differed; C-28/I2 cells are immortalized using SV40 large T antigen, which binds cellular proteins such 
as Rb and p53. Different p53 levels in primary chondrocytes and C-28/I2 cells may thus contribute to 
the differences in stretch responsiveness on short and long-term effects on VEGF [63]. The VEGF 
regulation by the p53 family members is complex and involves several transcription factors able to 
induce or repress VEGF in a cell context-dependent manner [63]. From a biological point of view,  
it does not make sense that a physiological process like daily joint loading induces pro-angiogenic 
factors like VEGF in a naturally avascular tissue, unless there is a feedback system to secondarily 
inhibit VEGF’s unwanted action. The high-affinity receptor sVEGFR-1 may inhibit unwanted 
angiogenesis in articular cartilage through abolishing stretch-induced VEGF action; sVEGFR-1 is 
significantly induced immediately after stretching, but suppressed 24 h after stretching when VEGF is 
still maximally induced. Our data thus suggest that stretch may contribute to triggering pathological 
angiogenesis in cartilage and prompt caution with respect to unphysiological joint loading. The negative 
regulation of VEGF signaling is exerted, at least in part, by the alternatively spliced soluble VEGFR1 
variant and may be established to prevent VEGF from binding to VEGFR-1 or VEGFR2 [59]. Another 
interesting but yet unclear feature of VEGFR1 is that its different ligands (e.g., VEGFA, VEGFB) 
transduce distinct biological responses [59] and VEGFR1 might positively modulate VEGFR2 outputs. 
Whether these apparently opposing effects of VEGFR1 on VEGFR2 activity are strain-dependent and 
involved in chondrocyte differentiation at all also remains to be investigated. 
Another limitation of our study is that we stretched monolayer cells, whereas the 3D in situ loading  
mainly involves compression that leads to nuclear deformation of a potentially different order of 
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magnitude [64]. Despite our consistent responses, in vitro systems never accurately represent the  
in vivo situation. This limits the interpretation of our results towards the in vivo situation. An emerging 
pattern in many biological responses to VEGF is the contribution by more than one type of VEGF 
receptor, which shows the crucial role of balanced signaling. 
Unstrained cells showed a typical polygonal morphology, while strained cells showed a more 
prominently pronounced, very round nucleus (Figure 7). In addition, cellular filopodia appeared to be 
more pronounced in strained cells. Using uniaxial cyclic tensile strain, Greiner et al. [65] showed that 
initially cell protrusions are uniformly formed around cells. Upon de novo syntheses of ventral actin 
stress fibers, these protrusions line up perpendicular to the direction of the strain using similar tension 
system and 2%–8% strain [66]. We applied biaxial strain, which may explain the radial orientation of 
the filopodia. To our knowledge, this is the first report of scanning electron micrographs of strained 
chondrocytes. In vitro applied strains caused only marginally decreased mitochondrial metabolic 
activity in C-28I2 cells, while cell death in articular chondrocytes might already be in process when 
VEGF is re-upregulated by stress triggers in OA cartilage in vivo [67]. 
3. Experimental Section 
3.1. Cell Culture 
Human chondrocytes used in this study comprise the C-28/I2 cell line [68], a well-established 
model that has been shown to phenotypically resemble articular chondrocytes [69], and primary human 
articular chondrocytes. For the latter, after local ethical approval and informed consent, cartilage was 
obtained from the femoral head region of a young, non-arthritic patient undergoing reconstruction 
surgery. Briefly, full thickness cartilage was harvested, chopped into pieces, washed and subsequently 
digested overnight in Ham’s F-12 medium as reported earlier [6]. The following day, harvested cell were 
cultured in DMEM/F-12 with 10% of heat-inactivated FCS and 1% Penicillin–Streptomycin–
Amphotericin B. For all media and culture additives were purchased from Sigma–Aldrich (Steinheim, 
Germany). Experiments were performed at least in independent triplicates with, at least, technical 
duplicates. Sample sizes (n) are indicated per experiment in the legend. 
3.2. Mechanical Stimulation 
Upon seeding of 350,000 C-28/I2 cells and 300,000 primary chondrocytes on collagen type I 
(COL1) coated BioFlex® six-well plates (FlexCell® Int. Corp., Hillsborough, FL, USA), the mechanical 
stimulation of the chondrocytes was essentially performed as reported earlier by us [6], but with the 
following modifications: cells were statically pre-cultured in the BioFlex® plates overnight (20–24 h) 
in 2.5 mL culture medium in a FlexCell Strain Unit FX-4000 to facilitate adherence to the flexible 
membrane. Cells were stretched in an incubator (37 °C, 5% CO2) as previously described [61] and the 
medium was exchanged immediately prior to stretching. 
Briefly, a vacuum created under the six-well plates pulls the flexible-bottom membrane over a 
loading post, resulting in homogenous biaxial strain of up to 30% of substrate (i.e., membrane) 
elongation. The used Flexercell® Tension Plus™ unit FX-4000T setup has a minimum strain resolution 
capability of 0.7% to 20% elongation and delivers frequencies between 0.1 and 5 Hz with single  
Int. J. Mol. Sci. 2014, 15 15467 
 
 
cycle strain rates as high as 6.9 s−1 with infinitely small creep strains. The system delivers multi-cyclic 
strain rates (0.2–10 s−1) using square cyclic waveform of which we used cyclic stretch at a frequency  
of 0.5 and 1 Hz, respectively, for 12 h, and stretching between 1% and 16%, respectively. Wells with 
FlexStop™ posts to prevent pressure-induced stretching served as internal controls [6]. 
3.3. Biochemical Analyses 
Two micro liters of culture medium were collected either immediately after the stretching regime 
(t0) or 24 h later. Samples were centrifuged (20,000 rcf, 5 min, 4 °C) and cell-free supernatants stored 
at −70 °C until further use. 
Commercially available enzyme-linked immunosorbent assay (ELISA) kits were used to quantify 
the amount of hVEGF and hVEGFR-1 (synonym: Flt-1) (both from R&D Systems, Minneapolis, MN, 
USA) according to the manufacturer’s instructions. Briefly, medium samples and standards were 
incubated overnight at 4 °C in the pre-coated wells. Washing steps, incubation of target-specific, 
biotin-coupled secondary antibody, and detection antibody (horseradish peroxidase conjugated) was 
according to supplier’s guidelines. Enzymatic substrate (3,3',5,5'-tetramethylbenzidine) oxidation was 
quantified using a Infinite® PRO reader (Tecan Germany GmbH, Crailsheim, Germnay) at 450 nm. 
3.4. Cell Viability Assay 
Cell viability assays were performed by using the CellTiter-Blue® assay (Promega, Madison, WI, 
USA) according to the manufacturer’s description. The assay relies on the conversion of resazurin into 
the highly fluorescent resorufin by metabolically active cells. Briefly, upon applying cyclic 1/2 shine 
and square waveforms at 1 Hz and 8% stretching for 12 h, cells were washed once with 2 mL of  
1× PBS and then incubated in culture medium for 24 h (controls), while the other cells were incubated 
with 0.2 mL of CellTiter-Blue® reagent (1:5). After 60, 90 and 120 min, 0.1 mL of the reagent were 
transferred into 96-well plates for optical density measurements at 570 nm (reference: 590 nm) in the 
Infinite® PRO reader against medium blanks. 
3.5. Transient Transfections and Dual Luciferase Assays 
Bacterial transformations and reporter plasmid DNA purifications were performed as described by 
Fragoulis et al. [70]. The 2.65 kb fragment of the human VEGF-A promoter region from plasmid 
pVEGF-KpnI (ATCC®, American Type Culture Collection, Manassas, VA, USA) or the 25 bp human 
hypoxia-responsive element (HRE) was cloned into the MluI site of the mcs pGL3-basic luciferase 
reporter vector (Promega, Madison, WI, USA). Both promoter reporter plasmids were then transiently 
co-transfected with the constitutively active reporter Renilla luciferase vector phRL-TK (Promega, 
Madison, WI, USA) into chondrocytes. After overnight incubation, reporter cells were used in 
mechanical stimulation experiments on BioFlex® plates (see above). 
Quantification of stretch-induced promoter activation by dual luciferase assays was performed 
exactly as reported earlier by Fragoulis et al. [70]. 
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3.6. Immunofluoresence 
To visualize changes in VEGF and VEGFR-1 expression on cellular level, C-28/I2 chondrocytes 
were fixed for 30 min in a neutral 4% v/v formalin solution (Sigma–Aldrich) after a 12 h lasting 8% 
cyclic square waveform stretch regime at 0.5 Hz. Cells on pieces of dissect BioFlex® silicone membranes 
were then permeabilized in 0.1% of Triton X-100 (Sigma–Aldrich) for 10 min and washed 3 times for  
5 min in Tris-Buffer (25 mM, pH 7.4) essentially as described earlier [71]. Blocking occurred in 1.5% 
BSA in Tris-Buffer (10 min) prior to incubation with polyclonal anti-VEGF (Santa Cruz, sc-507; 1:50)  
and anti-VEGFR-1 (Santa Cruz, sc-316; 1:30) antibodies overnight at 4 °C. After washing, antigens 
were visualized using secondary Alexa-Fluor® 488 labeled antibodies (Invitrogen, Karlsruhe, Germany; 
1:250) and analyzed imbedded in Shandon Immu-Mount™ (Thermo Scientific, Pittsburgh, PA, USA). 
Nuclear counterstaining was performed with Hoechst 33258 (Molecular Probes®, Invitrogen, 
Karlsruhe, Germany; bisBenzimide pentahydrate, 1:200) in 1× neutral PBS. Pictures were made using 
AxioVision Release 4.8.2 (Carl Zeiss MicroImaging GmbH, Jena, Germany). Normalized fluorescent 
signal densities were measured as reported earlier [72] and according to [73]. Quantification was 
performed using ImageJ freeware [74]. 
3.7. Scanning Electron Microscopy (SEM) 
Morphological changes in chondrocytes subjected to mechanical stimulation were assessed using 
SEM. Following a 12 h lasting 8% stretch regime at 1 Hz, C-28/I2 cells were immediately fixed in  
3% v/v EM-grade glutaraldehyde (Sigma–Aldrich, G5882) in a 0.1 M Sörensen phosphate buffer  
(pH 7.4; 13 mM NaH2PO4 × H2O; 87 mM Na2HPO4 × 2H2O; all Sigma–Aldrich). Cells were cut out 
with their BioFlex® silicone membrane and, upon routine dehydration in ethanol, critical point dried  
in liquid CO2 in a CPD 010 critical point dryer (BAL-TEC AG, Balzers, FL, USA). The samples  
were coated with 30 nm of gold in a SCD 500 sputter-coater (Leica Microsystems, Wetzlar, 
Deutschland) and analysed in a FEI/Philips XL 30 FEG ESEM (FEI, Frankfurt, Germany) in a high 
vacuum environment. 
3.8. Statistics 
Data are presented using GraphPad Prism 5 (La Jolla, CA, USA), showing the averages with 
standard deviation. Significance was tested using parametric, two-sided t-test using the average and 
significance was p ≤ 0.05. 
4. Conclusions 
Probably the most intriguing aspect of our study is that the high affinity receptor VEGFR-1 (Ftl-1) 
was less stretch-inducible than its ligand, VEGF-A. In addition, the secretion of the major VEGF 
decoy receptor, sVEGFR-1 (sFlt-1), appeared to be strain suppressible. 
In recent years there has been an impressive development of clinical therapies aiming to enhance or 
suppress VEGF/VEGFR function. That even relatively short-term suppression of VEGFR function 
might lead to suppression of blood vessel formation is now obvious from studies in mouse models [60] 
and has significant potential as a means to fine-tune VEGF-based anti-OA therapies. Strain-induced 
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sVEGFR-1 suppression in the long-term may therefore be detrimental to hyaline cartilage and suggests 
that even 4% relative elongation may be supra-physiological for chondrocytes. 
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